Late Breaking Abstract - Real-life characteristics and management of patients with fibrosing interstitial lung disease: INSIGHTS-ILD registry

This study aims to obtain real-life data on the characteristics and treatment trajectories of patients with fibrosing interstitial lung disease (fILD). INSIGHTS-ILD is an ongoing prospective registry for fILDs conducted at 32 expert sites across Germany. fILD patients are eligible if single breath diffusion capacity of the lung for carbon monoxide (DLCO) ≤80% pred., interstitial lung fibrosis >10% on HRCT, and are on any active anti-inflammatory and/or antifibrotic therapy. Criteria of progression were not mandatory for inclusion. Patients with IPF are excluded. Study registration: DRKS00027389, EMA RWD Catalogue 1000000161. Characteristics of the 655 patients in the interim analysis are shown in Figure 1. <fig><object-id>erj;64/suppl_68/PA3416/F1</object-id><object-id>F1</object-id><object-id>F1</object-id><graphic></graphic></fig>Current treatment included oral steroids (62.6%), antifibrotic therapy (50.5%), azathioprine (14.4%), MTX (10.2%) and MMF (11.1%). Mean quality of life on the 0-100 visual analogue scale was 58±19 points. Patients on antifibrotic therapy, compared to those not on such therapy were older, more often male, had a lower FVC and DLCO, and a higher prevalence of INBUILD criteria for progression (72.7% vs. 40.1%). The patient characteristics in this registry closely resemble those observed in randomized controlled trials and non-interventional studies of fILD, with individuals on antifibrotic therapy displaying a more severe disease profile.

Authors

Institutions

Publication Details

Published
2024-09-14
DOI
https://doi.org/10.1183/13993003.congress-2024.pa3416
Primary Topic
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Late Breaking Abstract - Real-life characteristics and management of patients with fibrosing interstitial lung disease: INSIGHTS-ILD registry

Heinrike Wilkens, Markus Polke, Martin Schwaiblmair, Jürgen Behr et al.
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
article

Late Breaking Abstract - Real-life characteristics and management of patients with fibrosing interstitial lung disease: INSIGHTS-ILD registry

Heinrike Wilkens, Markus Polke, Martin Schwaiblmair, Jürgen Behr, Stephan Eisenmann, Stephan Budweiser, Sven Glaeser, Ralf Ewert, Hans‐Joachim Kabitz, Ioana Andreica, Christine Pausch, Hubert Wirtz, David Pittrow, Antje Prasse, Tobias Veit, Lars Hagmeyer, Wolfgang Gesierich, Jens Klotsche, Peter Schramm, Ekaterina Krauss, Marion Frankenberger, Daniel Grund, Francesco Bonella, Werner von Wulffen, Achim Grünewaldt, Stephan Walterspacher, Andreas Guenther, Michael Westhoff, J Kirschner, Bernd Seese, Dirk Koschel, Martin Claussen, Claus-Peter Kreutz, Matthias Held, Sabine Haberl, Karine Thabaret, Frank Reichenberger, Lea Drobbe, Julia Wälscher, Heike Biller, Dirk Skowasch, Philipp Markart, Michael Kreuter, M. Weber, F. Joachim Meyer, Ulrich Neff, Claus Neurohr, Christian Grohé
article en

Abstract

This study aims to obtain real-life data on the characteristics and treatment trajectories of patients with fibrosing interstitial lung disease (fILD). INSIGHTS-ILD is an ongoing prospective registry for fILDs conducted at 32 expert sites across Germany. fILD patients are eligible if single breath diffusion capacity of the lung for carbon monoxide (DLCO) ≤80% pred., interstitial lung fibrosis >10% on HRCT, and are on any active anti-inflammatory and/or antifibrotic therapy. Criteria of progression were not mandatory for inclusion. Patients with IPF are excluded. Study registration: DRKS00027389, EMA RWD Catalogue 1000000161. Characteristics of the 655 patients in the interim analysis are shown in Figure 1. <fig><object-id>erj;64/suppl_68/PA3416/F1</object-id><object-id>F1</object-id><object-id>F1</object-id><graphic></graphic></fig>Current treatment included oral steroids (62.6%), antifibrotic therapy (50.5%), azathioprine (14.4%), MTX (10.2%) and MMF (11.1%). Mean quality of life on the 0-100 visual analogue scale was 58±19 points. Patients on antifibrotic therapy, compared to those not on such therapy were older, more often male, had a lower FVC and DLCO, and a higher prevalence of INBUILD criteria for progression (72.7% vs. 40.1%). The patient characteristics in this registry closely resemble those observed in randomized controlled trials and non-interventional studies of fILD, with individuals on antifibrotic therapy displaying a more severe disease profile.

Goethe University Frankfurt (DE), Johannes Gutenberg University Mainz (DE), Heidelberg University (DE), Universitätsmedizin Greifswald (DE), University Hospital Bonn (DE), University Hospital Augsburg (DE), University Hospital Heidelberg (DE), LMU Klinikum (DE), München Klinik Bogenhausen (DE), Medizinische Hochschule Hannover (DE), Augenklinik Heidelberg (DE), Ruhrlandklinik (DE), Rheumazentrum Ruhrgebiet (DE), University Medical Center of the Johannes Gutenberg University Mainz (DE), German Rheumatism Research Centre (DE), Accadis Hochschule Bad Homburg (DE), Nuremberg Hospital (DE), Zentralklinik Bad Berka (DE), Vivantes Klinikum (DE), Universitätsmedizin Göttingen (DE), Frauenklinik Heidelberg (DE), Asklepios Fachkliniken München-Gauting (DE), University Hospital Leipzig (DE), BioClinicum (Russia) (RU), Krankenhaus Bethanien (DE), RoMed Kliniken (DE), German Center for Lung Research (DE), Universities of Giessen and Marburg Lung Center (DE), University Hospital Frankfurt (DE), Lungenklinik Hemer (DE), GWT-TUD (Germany) (DE), Klinikum Konstanz (DE), LungenClinic Grosshansdorf (DE), Klinikum Würzburg Mitte (DE), University Hospital in Halle (DE), Klinikum Fulda (DE), University Hospital Carl Gustav Carus (DE), Technische Universität Dresden (DE), Ludwig-Maximilians-Universität München (DE)
Zero hunger
Openalex Percentile: Top 63%
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.